First tranche Offer: 270,000 shares at A$1 per share to up to 8 investors. (Closed)

Second tranche Offer: 2,045,082 shares at A$2.40 per share to 15 investors (2 million shares subscribed at A$2.40 each with consideration being 80,000 of crypto tokens at A$60 per token. Pre-Listing token is currently traded @ A$100 and the value owned by COVIRIX is A$8 million.  (Closed) including 18,000 shares issued to one party at A$2.40 per share as fee for service. 

Third tranche* Offer: 5 million shares at US$3 per share raising US$15 million to cover costs of phase 1+2 clinical trials, expansion of executive and administrative support, and primary listing expenses. (Open)

Total issued shares on completion of third Tranche Offer will be 67.315 million.

*To participate in the above Offer, investor needs to complete and sign the Shares Placement Application Form and return it to COVIRIX at Level 1, 237 East Boundary Road, Bentleigh East, Victoria 3165, Australia. 

Fourth tranche Offer IPO Offer: 18.75 million shares at US$4 per share to raise US$75 million pre stock exchange listing.

Total expected issued capital after IPO 86.065 million shares.

Total shares already issued since inception 62,325 million to 28 Professional and Sophisticated investors.

The Board of COVIRIX Medical reserves the absolute right to change its Capital Management Plan as to price, quantity and timing of securities to be offered prior to each tranche of the Offer